29 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
to reach our goal of 10,000 annual doses by the end of 2025. The expansion of our partnership with Novartis demonstrates our commitment to ensuring
6-K
LEGN
Legend Biotech Corp
29 Mar 24
Current report (foreign)
8:00am
a specified percentage of the capacity of Qualified Suites for each 6-month period under the Agreement (the “Volume Commitment”), subject … to adjustment for any Released Suites. If the Collaboration Partners fail to purchase sufficient batches to achieve the Volume Commitment (other than
6-K
EX-99.1
LEGN
Legend Biotech Corp
23 Feb 24
Current report (foreign)
7:16am
be reviewed by the European Commission which renders the final decision on approval.
“This milestone demonstrates our commitment to transforming
F-3ASR
EX-4.5
7it0yp
26 May 23
Automatic shelf registration (foreign)
9:01am
F-3ASR
EX-4.6
cauf62j c4
26 May 23
Automatic shelf registration (foreign)
9:01am
F-3ASR
EX-4.7
m4rbg 6sot8si1e2s
26 May 23
Automatic shelf registration (foreign)
9:01am
6-K
EX-99.1
fgulgvt7zjge
3 Nov 22
Legend Biotech Corporation 6-K
4:09pm
6-K
EX-99.3
r0lmo s4mdo8
25 Jul 22
Legend Biotech Corporation Announces Proposed Public Offering
4:07pm
6-K
EX-99.1
0vtsb44nr6ty8i
26 May 22
Legend Biotech Corp. 6-K
6:02am
F-3
EX-10.1
umqze39iecpmpy1b1
2 Jul 21
Shelf registration (foreign)
7:36am
6-K
EX-99.1
fxaef3
12 May 21
Legend Biotech Reports Compelling New and Updated Data from BCMA CAR-T Program at Upcoming 2021 ASCO and EHA Meetings
1:54pm
20-F
9itaymv0wf0goonk fmw
2 Apr 21
Annual report (foreign)
8:10am
S-8 POS
EX-10.2
srv9sfv
4 Sep 20
Registration of securities for employees (post-effective amendment)
4:19pm
S-8
EX-10.2
9mgzojhyr034218n8td
26 Jun 20
Registration of securities for employees
4:11pm
424B4
p6432hb6zece
8 Jun 20
Prospectus supplement with pricing info
9:07am
F-1/A
EX-10.7
0owjzr llgrcg
29 May 20
Registration statement (foreign) (amended)
8:32am